| Name | Leukemia (A:m6A) |
| Description | FTO highly expressed in AML t(11q23)/MLL rearrangements, t(15;17)/PML-RARA, FLT3-ITD and/or NPM1 mutations. FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and RARA by reducing m6A levels in these mRNA transcripts. |
| Related RNA reaction | A:m6A |
| Found in RNA | mRNA |
| Modified Transcript | ASB2 and RARA |
| Mapping Technology | MeRIP-seq |
| Quantification techniques | m6A quantification, Gene-Specific m6A qPCR |
| Acronym | Full name | Enzyme Role | Organism | Comment |
|---|---|---|---|---|
| FTO | Alpha-ketoglutarate-dependent dioxygenase FTO | oncogene | Homo sapiens |
| ID | Title | Authors | Journal | Details | ||
|---|---|---|---|---|---|---|
| 1064 | FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNADemethylase. | Li Z | Cancer Cell | [details] | 28017614 | 10.1016/j.ccell.2016.11.017 |